Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine. It operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business. Trinity Biotech's blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections.
|Headquarters||IDA Business Park|
BRAY, Ireland 18
|Executive Chairman of the Board||Ronan O'Caoimh|
|Chief Financial Officer, Secretary||Kevin Tansley|
|Chief Operating Officer, Executive Director||Rory Nealon|
|Chief Scientific Officer, and Vice President Cardiac||Eric Brouwer|
|Executive Director||James Walsh|
|Shares Out.||24.0M||Book Value||$8.93|
|Annual Dividend Rate||0.22 USD||Price/Sales (TTM)||2.7|
|Ex-Div Date||6/5/15||P/Cash Flow (TTM)||--|
|Pay Date||7/1/15||Operating Margin||13.42%|
*GAAP = prior to non-GAAP analyst adjusted earnings.